VIVUS (Nasdaq: VVUS) shocked the market with seemingly unbelievable first quarter results, sending shares over 10% higher. They have since steadily declined. The lesson as always: if something seems to good to be true, it probably is.
Sales of its obesity drug Qsymia doubled, but to the still low total of $9 million. More concerning prescriptions declined, despite the aggressive discount program for the drug.
In this episode of Market Check-Up, the Motley Fool's health-care focused investing show, analysts David Williamson and Michael Douglass discuss the quarterly results, obesity drug competition, and ultimately why Vivus investors should be concerned.
Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!